IP Library › Granted Patent US 12,552,795
Granted Patent B2
US 12,552,795 · App. 17/602,770 · Granted Feb 17, 2026

Pyrrolotriazine derivatives for treating kit-and PDGFRA-mediated diseases

Inventors: Joseph L. Kim (Cambridge, MA); Thomas A. Dineen (Cambridge, MA); Timothy Guzi (Cambridge, MA)
Assignee: Blueprint Medicines Corporation
C07D487/04A61P43/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,552,795
App. No.
17/602,770
Granted
Feb 17, 2026
Kind
B2
Abstract

The present disclosure provides compounds of Formula I, pharmaceutical salts thereof, and/or solvates of any of the foregoing which are useful for treating diseases and conditions related to mutant KIT and PDGFRa and present an advantageously non-brain penetrant profile for treating diseases and conditions related to mutant KIT and PDGFRa. The present disclosure also provides methods for treating gastrointestinal stromal tumors and systemic mastocytosis.

Claims (10)

1 . A compound or a pharmaceutically acceptable salt thereof, wherein the compound is:

2 . The compound of claim 1 ,

3 . A compound or a pharmaceutically acceptable salt thereof, wherein the compound is:

4 . The compound of claim 3 ,

5 . A pharmaceutical composition comprising:

a compound of claim 1 or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable excipient.

6 . A pharmaceutical composition comprising:

a compound of claim 3 or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable excipient.

Assignments (5)
RELEASE OF SECURITY INTEREST (REEL/FRAME NUMBER 060616/0923) Recorded Jul 23, 2025
From: TAO TALENTS, LLC
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 072193/0847 →
RELEASE OF SECURITY INTEREST Recorded Jul 21, 2025
From: PROTOZOA INVESTMENTS, L.P.
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 071777/0840 →
SECURITY INTEREST Recorded Jul 8, 2022
From: BLUEPRINT MEDICINES CORPORATION
To: GARNICH ADJACENT INVESTMENTS S.A.R.L.
Reel/Frame 060465/0357 →
SECURITY INTEREST Recorded Jul 8, 2022
From: BLUEPRINT MEDICINES CORPORATION
To: TAO TALENTS, LLC
Reel/Frame 060616/0923 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2021
From: KIM, JOSEPH L.; DINEEN, THOMAS A.; GUZI, TIMOTHY
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 057797/0183 →
Continuity (4)
Provisional Application 62930240 · Nov 4, 2019
Provisional Application 62911016 · Oct 4, 2019
Provisional Application 62833529 · Apr 12, 2019
Related Publication 20220153748A1 · May 19, 2022
References Cited (80)
US 6982265B1 · Hunt et al. · 2006 [cited by applicant]
US 7244733B2 · Hunt et al. · 2007 [cited by applicant]
US 8609672B2 · Russu et al. · 2013 [cited by applicant]
US 9200002B2 · Hodous et al. · 2015 [cited by applicant]
US 9334263B2 · Hodous et al. · 2016 [cited by applicant]
US 9499522B2 · DiPietro et al. · 2016 [cited by applicant]
US 9688680B2 · Hodous · 2017 [cited by applicant]
US 9884861B2 · Hodous et al. · 2018 [cited by applicant]
US 9944651B2 · Hodous et al. · 2018 [cited by applicant]
US 9994552B2 · DiPietro et al. · 2018 [cited by applicant]
US 9994575B2 · Hodous et al. · 2018 [cited by applicant]
US 10000496B2 · Hodous et al. · 2018 [cited by applicant]
US 10829493B2 · Dineen · 2020 [cited by applicant]
US 20040186140A1 · Cherney et al. · 2004 [cited by applicant]
US 20230391780A1 · Dineen · 2023 [cited by applicant]
CN 102040494 · 2011 [cited by applicant]
CN 108191874A · 2018 [cited by applicant]
CN 110938077A · 2020 [cited by applicant]
CN 110950872A · 2020 [cited by applicant]
EP 0200968A1 · 1986 [cited by applicant]
JP 2008504366A · 2008 [cited by applicant]
WO 200071129A1 · 2000 [cited by applicant]
WO 200125220A1 · 2001 [cited by applicant]
WO 2003010158A1 · 2003 [cited by applicant]
WO 2003090912A1 · 2003 [cited by applicant]
WO 2004071460A2 · 2004 [cited by applicant]
WO 2004076450A1 · 2004 [cited by applicant]
WO 2005066176A1 · 2005 [cited by applicant]
WO 2005117909A2 · 2005 [cited by applicant]
WO 2005121147A1 · 2005 [cited by applicant]
WO 2006004636A2 · 2006 [cited by applicant]
WO 2006028524A2 · 2006 [cited by applicant]
WO 2007056170A2 · 2007 [cited by applicant]
WO 2007065100A1 · 2007 [cited by applicant]
WO 2007085188A1 · 2007 [cited by applicant]
WO 2008005956A2 · 2008 [cited by applicant]
WO 2009015254A1 · 2009 [cited by applicant]
WO 2009117157A1 · 2009 [cited by applicant]
WO 2010022055A2 · 2010 [cited by applicant]
WO 2010144345A1 · 2010 [cited by applicant]
WO 2011005119A1 · 2011 [cited by applicant]
WO 2011103196A1 · 2011 [cited by applicant]
WO 2012027495A1 · 2012 [cited by applicant]
WO 2013004551A1 · 2013 [cited by applicant]
WO 2013087578A1 · 2013 [cited by applicant]
WO 2014039714A2 · 2014 [cited by applicant]
WO 2014100620A2 · 2014 [cited by applicant]
WO 2014160521A1 · 2014 [cited by applicant]
WO 2015057873A1 · 2015 [cited by applicant]
WO 2015058129A1 · 2015 [cited by applicant]
WO 2016022569A1 · 2016 [cited by applicant]
WO 2017019442A1 · 2017 [cited by applicant]
WO 2017079140A1 · 2017 [cited by applicant]
WO 2018147626A1 · 2018 [cited by applicant]
WO 2018169373A1 · 2018 [cited by applicant]
WO 2018183712A1 · 2018 [cited by applicant]
WO 2019034128A1 · 2019 [cited by applicant]
WO 2019201194A1 · 2019 [cited by applicant]
WO 2019211463A1 · 2019 [cited by applicant]
WO 2020102095A1 · 2020 [cited by applicant]
WO 2020128850A1 · 2020 [cited by applicant]
WO 2021064590A1 · 2021 [cited by applicant]
McMahon et al. [cited by examiner]
Pinedo et al. [cited by examiner]
Antonescu, What lessons can be learned from the GIST paradigm that can be applied to other kinase-driven cancers. J Pathol. Jan. 2011;223(2):251-261. [cited by applicant]
Cairoli et al., Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. May 1, 2006;107(9):3463-8. [cited by applicant]
Cohen, The development and therapeutic potential of protein kinase inhibitors. Curr Opin Chem Biol. Aug. 1999;3(4):459-65. [cited by applicant]
Dhillon, Avapritinib: First Approval. Drugs. 2020;80(4):433-439. [cited by applicant]
Di et al., Demystifying brain penetration in central nervous system drug discovery. Miniperspective. J Med Chem. 2013;56(1):2-12. [cited by applicant]
Evans et al., A precision therapy against cancers driven by KIT/PDGFRA mutations. Sci Transl Med. 2017;9(414):eaao1690, 11 pages. [cited by applicant]
Lee et al., Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis. J Gastrointestin Liver Dis. Dec. 2013;22(4):413-8. [cited by applicant]
Paschka et al., Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. Aug. 20, 2006;24(24):3904-11. [cited by applicant]
Quintela et al., A Ready One-pot Preparation for Pyrrolo[2, 1-f]-[1,2,4]triazine and Pyrazolo[5, 1-c]pyrimido[4,5-e]-[1,2,4]triazine Derivatives. Tetrahedron. 1996;52(8):3037-3048. [cited by applicant]
Rankovic, CNS drug design: balancing physicochemical properties for optimal brain exposure. J Med Chem. 2015;58(6):2584-2608. [cited by applicant]
Schnittger et al., KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107:1791-1799. [cited by applicant]
Shallal et al., Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives. Eur J Med Chem. Jun. 2011;46(6):2043-57. [cited by applicant]
U.S. Appl. No. 16/842,969, filed Apr. 8, 2020, U.S. Pat. No. 10,829,493. [cited by applicant]
U.S. Appl. No. 18/031,714, filed Apr. 13, 2023, 2023-0391780. [cited by applicant]
U.S. Appl. No. 18/549,769, filed Sep. 8, 2023, 2024-0254130. [cited by applicant]
Patani et al., Bioisosterism: A Rational Approach in Drug Design. Chem Rev. Dec. 19, 1996;96(8):3147-3176. [cited by applicant]